Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

Hiddo J Lambers Heerspink; Glenn M Chertow; Tadao Akizawa; Paul Audhya; George L Bakris; Angie Goldsberry; Melissa Krauth; Peter Wilhelm Lund Linde; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Heidi Christ-Schmidt; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Dick de Zeeuw

doi:10.1093/ndt/gft445

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

Hiddo J Lambers Heerspink, Glenn M Chertow, Tadao Akizawa, Paul Audhya, George L Bakris, Angie Goldsberry, Melissa Krauth, Peter Wilhelm Lund Linde, John J McMurray, Colin J Meyer, Hans-Henrik Parving, Giuseppe Remuzzi, Heidi Christ-Schmidt, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Dick de Zeeuw

19 Citationer (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is the most important contributing cause of end-stage renal disease (ESRD) worldwide. Bardoxolone methyl, a nuclear factor-erythroid-2-related factor 2 activator, augments estimated glomerular filtration. The Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial was designed to establish whether bardoxolone methyl slows or prevents progression to ESRD. Herein, we describe baseline characteristics of the BEACON population.

Originalsprog	Engelsk
Tidsskrift	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Vol/bind	28
Udgave nummer	11
Sider (fra-til)	2841-50
Antal sider	10
ISSN	0931-0509
DOI	https://doi.org/10.1093/ndt/gft445
Status	Udgivet - nov. 2013

Adgang til dokumentet

10.1093/ndt/gft445

Citationsformater

Lambers Heerspink, H. J., Chertow, G. M., Akizawa, T., Audhya, P., Bakris, G. L., Goldsberry, A., Krauth, M., Linde, P. W. L., McMurray, J. J., Meyer, C. J., Parving, H.-H., Remuzzi, G., Christ-Schmidt, H., Toto, R. D., Vaziri, N. D., Wanner, C., Wittes, J., Wrolstad, D., & de Zeeuw, D. (2013). Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 28(11), 2841-50. https://doi.org/10.1093/ndt/gft445

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. / Lambers Heerspink, Hiddo J; Chertow, Glenn M; Akizawa, Tadao et al.
I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Bind 28, Nr. 11, 11.2013, s. 2841-50.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Lambers Heerspink, HJ, Chertow, GM, Akizawa, T, Audhya, P, Bakris, GL, Goldsberry, A, Krauth, M, Linde, PWL, McMurray, JJ, Meyer, CJ, Parving, H-H, Remuzzi, G, Christ-Schmidt, H, Toto, RD, Vaziri, ND, Wanner, C, Wittes, J, Wrolstad, D & de Zeeuw, D 2013, 'Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial', Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, bind 28, nr. 11, s. 2841-50. https://doi.org/10.1093/ndt/gft445

Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A et al. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2013 nov.;28(11):2841-50. doi: 10.1093/ndt/gft445

Lambers Heerspink, Hiddo J ; Chertow, Glenn M ; Akizawa, Tadao et al. / Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus : the Occurrence of renal eveNts (BEACON) trial. I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2013 ; Bind 28, Nr. 11. s. 2841-50.

@article{c45f9cae4505441fa24cc97522a95c2b,

title = "Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial",

abstract = "Type 2 diabetes mellitus (T2DM) is the most important contributing cause of end-stage renal disease (ESRD) worldwide. Bardoxolone methyl, a nuclear factor-erythroid-2-related factor 2 activator, augments estimated glomerular filtration. The Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial was designed to establish whether bardoxolone methyl slows or prevents progression to ESRD. Herein, we describe baseline characteristics of the BEACON population.",

author = "{Lambers Heerspink}, {Hiddo J} and Chertow, {Glenn M} and Tadao Akizawa and Paul Audhya and Bakris, {George L} and Angie Goldsberry and Melissa Krauth and Linde, {Peter Wilhelm Lund} and McMurray, {John J} and Meyer, {Colin J} and Hans-Henrik Parving and Giuseppe Remuzzi and Heidi Christ-Schmidt and Toto, {Robert D} and Vaziri, {Nosratola D} and Christoph Wanner and Janet Wittes and Danielle Wrolstad and {de Zeeuw}, Dick",

year = "2013",

month = nov,

doi = "10.1093/ndt/gft445",

language = "English",

volume = "28",

pages = "2841--50",

journal = "Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",

issn = "0931-0509",

publisher = "OXFORD UNIV PRESS",

number = "11",

}

TY - JOUR

T1 - Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus

T2 - the Occurrence of renal eveNts (BEACON) trial

AU - Lambers Heerspink, Hiddo J

AU - Chertow, Glenn M

AU - Akizawa, Tadao

AU - Audhya, Paul

AU - Bakris, George L

AU - Goldsberry, Angie

AU - Krauth, Melissa

AU - Linde, Peter Wilhelm Lund

AU - McMurray, John J

AU - Meyer, Colin J

AU - Parving, Hans-Henrik

AU - Remuzzi, Giuseppe

AU - Christ-Schmidt, Heidi

AU - Toto, Robert D

AU - Vaziri, Nosratola D

AU - Wanner, Christoph

AU - Wittes, Janet

AU - Wrolstad, Danielle

AU - de Zeeuw, Dick

PY - 2013/11

Y1 - 2013/11

N2 - Type 2 diabetes mellitus (T2DM) is the most important contributing cause of end-stage renal disease (ESRD) worldwide. Bardoxolone methyl, a nuclear factor-erythroid-2-related factor 2 activator, augments estimated glomerular filtration. The Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial was designed to establish whether bardoxolone methyl slows or prevents progression to ESRD. Herein, we describe baseline characteristics of the BEACON population.

AB - Type 2 diabetes mellitus (T2DM) is the most important contributing cause of end-stage renal disease (ESRD) worldwide. Bardoxolone methyl, a nuclear factor-erythroid-2-related factor 2 activator, augments estimated glomerular filtration. The Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial was designed to establish whether bardoxolone methyl slows or prevents progression to ESRD. Herein, we describe baseline characteristics of the BEACON population.

U2 - 10.1093/ndt/gft445

DO - 10.1093/ndt/gft445

M3 - Journal article

C2 - 24169612

SN - 0931-0509

VL - 28

SP - 2841

EP - 2850

JO - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

IS - 11

ER -

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater